Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEM8-Fc
- Development stage
- Preclinical
- Lead developer
- Planet Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
TEM8-Fc is a recombinant fusion protein developed by Planet Biotechnology, consisting of the extracellular domain of Tumor Endothelial Marker 8 (TEM8) fused to an Fc immunoglobulin fragment. TEM8, also known as Anthrax Toxin Receptor 1 (ANTXR1), is a cell surface protein that serves as a receptor for the anthrax toxin produced by *Bacillus anthracis*. TEM8-Fc is designed to act as a soluble decoy receptor that competitively binds to the Protective Antigen (PA) component of the anthrax toxin. By sequestering PA, the fusion protein prevents the formation of the toxin complex on host cell surfaces and the subsequent translocation of lethal and edema factors into the cytoplasm. The drug is currently in the preclinical stage, with research-grade protein available for study.
- Other names
- TEM8-fusion proteinTEM-8-fusion proteinTEM 8-fusion proteinTumor Endothelial Marker 8-Fc fusion proteinTEM8-Fc-Planet Technologies-TEM8-fusion proteinTEM-8-Fc-Planet Technologies-TEM8-fusion proteinTEM 8-Fc-Planet Technologies-TEM8-fusion protein
02
Targets
PKM2 (Pyruvate kinase M2 isoform)PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on TEM8-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEM8-Fc.